Joseph Havlik
Infectious Disease · Austell, GANPI 1144325432
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,305 of the $53,094 with a category attached, or 75.9%. Gilead accounts for 88.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $16,969 and has fallen 89.1% since, to $1,845 in 2024. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $135.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$47K
- Paratek Pharmaceuticals, Inc.$2K
- Viiv Healthcare Company$669
- AbbVie$451
- Insmed, Inc.$437
- Shionogi Inc$404
- plus $3K from 20 others
What the payments were for
- Consulting fees$2,5005%
- Speaking & faculty fees$40,30576%
- Travel & lodging$2,3024%
- Food & beverage$7,63114%
- Education$3521%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 168 | $46,723 |
| Paratek Pharmaceuticals, Inc. | 4 | $1,814 |
| Viiv Healthcare Company | 41 | $669 |
| AbbVie(2 entities) | 24 | $451 |
| Insmed, Inc. | 15 | $437 |
| Shionogi Inc | 17 | $404 |
| Merck | 20 | $397 |
| Melinta Therapeutics, LLC | 22 | $355 |
| Johnson & Johnson | 19 | $230 |
| La Jolla Pharmaceutical Company | 10 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $206 |
| Octapharma USA, Inc. | 2 | $183 |
| Pfizer | 8 | $158 |
| Astellas Pharma US Inc | 6 | $140 |
| Tetraphase Pharmaceuticals, Inc. | 7 | $130 |
| Janssen Products, LP | 2 | $118 |
| Comsort, Inc | 1 | $100 |
| Theratechnologies Inc. | 5 | $86 |
| CSL Behring | 2 | $55 |
| Grifols USA, LLC | 3 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $22 |
| Amgen | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,094 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 54 | $210,566 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $136,272 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $107,455 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $35,283 |
| ValacyclovirValacyclovir Hcl | 14 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy, Descovy | $46,723 | $382,122104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Austell
- Mir HusainAustell$6K
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.